An estimated 1 in 68 children in the United States has autism. The neurodevelopmental disorder, which impairs communication and social interaction skills, can be treated with medications and behavioral therapies, though there is no cure.
Now, University of Missouri researchers have found that a medication commonly used to treat high blood pressure and irregular heartbeats may have the potential to improve some social functions of individuals with autism.
“Propranolol was first reported to improve the language and sociability skills of individuals with autism in 1987, but it was not a randomized, controlled trial, and there has been little follow-up research on this drug in relation to autism,” said David Beversdorf, M.D., the senior author of the study.
“While its intended use is to treat high blood pressure, propranolol has been used off-label to treat performance anxiety for several years.”
“However, this is the first study to show that a single dose of propranolol can improve the conversational reciprocity skills of individuals with autism.”
Led by Rachel Zamzow, graduate student with the MU Center for Translational Neuroscience, 20 individuals with autism were recruited from the MU Thompson Center and given either a 40-milligram dose of propranolol or a placebo pill.
An hour after administration, the researchers had a structured conversation with the participants, scoring their performance on six social skills necessary to maintain a conversation:
Staying on topic, sharing information, reciprocity or shared conversation, transitions or interruptions, nonverbal communication and maintaining eye contact.
The researchers found the total communication scores were significantly greater when the individual took propranolol compared to the placebo.
“Though more research is needed to study its effects after more than one dose, these preliminary results show a potential benefit of propranolol to improve the conversational and nonverbal skills of individuals with autism,” said Beversdorf.
“Next, we hope to study the drug in a large clinical trial to establish the effects of regular doses and determine who would most likely benefit from this medication. Additional studies could lead the way for improved treatments for individuals with autism.”
News source: University of Missouri-Columbia. The content is edited for length and style purposes.
Figure legend: This Knowridge.com image is credited to Wikipedia.